Assessment of the risk of malignancy in Bethesda III thyroid nodules: a comprehensive review
Rao, Karthik Nagaraja; Randolph, Gregory W.; Lopez, Fernando; Zafereo, Mark; Coca-Pelaz, Andrés; Piazza, Cesare; Dange, Prajwal; Rodrigo, Juan Pablo; Stenman, Göran; de Keizer, Bart; Nixon, Iain; Sinha, Shriyash; Leboulleux, Sophie; Mäkitie, Antti A.; Agaimy, Abbas; Thompson, Lester; Ferlito, Alfio
(2024) Endocrine, volume 85, issue 2, pp.
(Article)
Abstract
The increasing prevalence of thyroid cancer emphasizes the need for a thorough assessment of risk of malignancy in Bethesda III nodules. Various methods ranging commercial platforms of molecular genetic testing (including Afirma® GEC, Afirma® GSC, ThyroSeq® V3, RosettaGX®, ThyGeNEXT®/ThyraMIR®, ThyroidPRINT®) to radionuclide scans and ultrasonography have been investigated to provide
... read more
a more nuanced comprehension of risk estimation. The integration of molecular studies and imaging techniques into clinical practice may provide clinicians with improved and personalized risk assessment. This integrated approach we feel may enable clinicians to carefully tailor interventions, thereby minimizing the likelihood of unnecessary thyroid surgeries and overall crafting the optimal treatment. By aligning with the evolving landscape of personalized healthcare, this comprehensive strategy ensures a patient-centric approach to thyroid nodule and thyroid cancer management.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Artificial intelligence, Bethesda system, Molecular testing, Risk assessment, Thyroid neoplasms, Endocrinology, Diabetes and Metabolism, Endocrinology
ISSN: 1355-008X
Publisher: Humana Press
Note: Publisher Copyright: © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.
(Peer reviewed)